Theranos founder Elizabeth Holmes was sentenced Friday to 135 months—11 years and three months—in federal prison for defrauding investors in the blood-testing startup, bringing the criminal case against one of Silicon Valley’s most celebrated founders to a major turning point. U.S. District Judge Edward J. Davila also imposed three years of supervised release and ordered Holmes to surrender on April 27, 2023, according to the U.S. Attorney’s Office. Restitution will be determined at a later hearing; the court did not impose a fine.

The sentence follows a January jury verdict that found Holmes guilty of one count of conspiracy to commit wire fraud against investors and three substantive wire-fraud counts tied to investor transfers totaling more than $140 million. The verdict announcement also underscored what the jury did not find: Holmes was acquitted on the patient-fraud conspiracy count and three patient-related wire-fraud counts, while jurors could not reach unanimous verdicts on three additional investor counts. That mixed verdict shapes the legal meaning of Friday’s punishment: Holmes is being sentenced for investor fraud, not for every allegation associated with Theranos.

The court punished a financing fraud built around technology claims

Theranos raised money on the promise that its proprietary analyzers could perform a broad range of laboratory tests from very small blood samples quickly and accurately. Trial evidence, as summarized by prosecutors, showed that Holmes knew the company’s technology had significant accuracy and reliability problems, could perform only a limited number of tests, and often relied on conventional analyzers purchased from other manufacturers. Prosecutors also said Holmes misrepresented Theranos’s financial condition, commercial relationships and validation by pharmaceutical companies.

The federal case traces back to a 2018 criminal charging announcement alleging separate schemes to defraud investors and paying patients. The indictment accused Holmes and former Theranos president Ramesh “Sunny” Balwani of using claims about the company’s testing technology, finances and deployment to induce investment and the purchase of laboratory services. Holmes denied criminal wrongdoing and went to trial rather than resolving the charges through a plea.

Friday’s sentencing therefore represents the court’s response to a form of technology-company fraud in which technical representations were inseparable from capital formation. Investors were not merely buying a financial projection; they were being asked to believe that a privately held company had solved difficult scientific and engineering problems. When those claims are materially false, ordinary startup uncertainty can cross into criminal fraud.

Civil regulators had raised the same core misrepresentation problem years earlier

Long before the criminal verdict, the Securities and Exchange Commission brought a civil case alleging that Holmes, Balwani and Theranos raised more than $700 million through false or exaggerated claims about the company’s technology, business and financial performance. The SEC’s March 2018 enforcement announcement said investors were led to believe the company’s portable analyzer could perform comprehensive testing from finger-stick samples even though the technology’s capabilities were substantially more limited.

Holmes settled the SEC charges without admitting or denying the allegations. The resolution included a $500,000 penalty, relinquishment of voting control and millions of shares, and a 10-year bar on serving as an officer or director of a public company. A related SEC litigation release described the parallel civil actions against Holmes and Balwani and the agency’s view that the fundraising campaign depended on materially misleading statements to private investors.

The civil and criminal processes use different legal standards and remedies, but the overlap is instructive. Securities enforcement focuses on protecting investors and markets, while the criminal case required prosecutors to prove charged offenses beyond a reasonable doubt. The January verdict established that the jury found that burden satisfied on four investor-related counts.

The separate Balwani verdict shows the case reached beyond a single founder

Theranos’s former president and chief operating officer, Balwani, was tried separately. In July, a different federal jury convicted him of two conspiracy counts and 10 wire-fraud counts involving both investors and patients. The Justice Department’s July 7 announcement said trial evidence showed Balwani made false claims about the company’s testing technology, revenue projections, Walgreens expansion and ability to produce reliable blood-test results. His sentencing remains pending.

The separate trials matter because they prevent the Theranos failure from being reduced to a simple corporate morality tale centered on one personality. Prosecutors presented evidence of a management structure in which multiple senior leaders communicated with investors, oversaw operations and participated in claims about the company’s capabilities. The criminal verdicts against both former executives indicate that two juries independently found fraudulent conduct proven beyond a reasonable doubt, though the counts and victim groups differed.

At Holmes’s sentencing, Judge Davila confronted the difficult question of how severely to punish a founder whose company pursued genuine scientific ambitions but whose fundraising conduct the jury found criminal. Prosecutors sought a substantially longer term, while defense lawyers argued for a far more limited sentence. A contemporaneous courtroom account reported that Davila calculated losses attributable to Holmes’s fraud in the hundreds of millions of dollars and emphasized the importance of investors being able to make decisions free from misrepresentation.

The sentence draws a sharper line around startup promotion

Technology companies routinely describe products that are unfinished, uncertain or dependent on future breakthroughs. That does not make ambitious forecasting unlawful. The boundary becomes legally significant when executives knowingly make material false statements about what a product can do, what customers or partners have validated, or what financial performance has already occurred. The Theranos prosecution has forced that distinction into unusually public view.

The case also exposes a governance problem common to highly valued private companies. Theranos attracted sophisticated investors, prominent directors and extensive media attention without the continuous disclosure obligations imposed on public companies. Private-company status does not remove antifraud law, but it can place greater weight on due diligence, board oversight and the accuracy of information supplied directly by management.

Holmes’s sentence will not by itself establish a new legal doctrine for startups; wire fraud and conspiracy are long-standing federal crimes. Its significance lies instead in applying those traditional rules to a company whose value depended heavily on a technological narrative. The Justice Department’s sentencing release described the offense in conventional terms—defrauding investors of hundreds of millions of dollars—even though the setting was one of Silicon Valley’s most closely watched ventures.

Holmes remains able to pursue post-trial motions and appellate review, and Friday’s sentence does not determine the final restitution amount. But the immediate legal record is now clear: a founder once associated with a multibillion-dollar biotechnology company has been convicted on four investor-fraud counts and sentenced to more than 11 years in federal prison. For the technology sector, the lesson is less about whether founders may make bold claims than about the obligation to distinguish aspiration from fact when those claims are used to obtain other people’s money.